(MedPage Today) — MADRID — Dual antiplatelet therapy (DAPT) didn’t improve outcomes after coronary artery bypass grafting (CABG) for an acute coronary syndrome (ACS) but did increase risks, the TACSI randomized trial showed.
With ticagrelor…
Source link : https://www.medpagetoday.com/meetingcoverage/esc/117248
Author :
Publish date : 2025-09-01 20:34:00
Copyright for syndicated content belongs to the linked Source.
